H Lundbeck A/S Total Assets

Latest as of December 2025: Dkr54.01 Billion DKK ≈ $8.45 Billion USD

H Lundbeck A/S total assets. Based on the latest financial reports, H Lundbeck A/S (HLUN-A) holds total assets worth Dkr54.01 Billion DKK (≈ $8.45 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see HLUN-A market cap overview for the company's overall valuation and market capitalisation.

Total Assets of H Lundbeck A/S (2004–2025)

Total assets of H Lundbeck A/S from 2004 to 2025. This chart illustrates how H Lundbeck A/S's total assets have evolved over time, based on quarterly financial data. See H Lundbeck A/S stock price for real-time trading data and today's change.

H Lundbeck A/S - Asset Composition Analysis

H Lundbeck A/S Total Assets Breakdown (December 2025)

H Lundbeck A/S total assets breakdown as of December 2025. H Lundbeck A/S's total assets of Dkr54.01 Billion consist of 23.7% current assets and 76.3% non-current assets.

Asset Category Amount (DKK) % of Total Assets
Cash & Equivalents Dkr0.00 6.4%
Accounts Receivable Dkr4.55 Billion 8.4%
Inventory Dkr4.47 Billion 8.3%
Property, Plant & Equipment Dkr0.00 0.0%
Intangible Assets Dkr28.77 Billion 53.3%
Goodwill Dkr7.01 Billion 13.0%

Asset Composition Trend (2004–2025)

This chart illustrates how H Lundbeck A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore H Lundbeck A/S current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: H Lundbeck A/S's current assets represent 23.7% of total assets in 2025, a decrease from 51.7% in 2004.
  • Cash Position: Cash and equivalents constituted 6.4% of total assets in 2025, down from 25.2% in 2004.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 65.0% of total assets, an increase from 14.0% in 2004.
  • Asset Diversification: The largest asset category is intangible assets at 53.3% of total assets.

H Lundbeck A/S Competitors by Total Assets

Key competitors of H Lundbeck A/S based on total assets are shown below.

Company Country Total Assets
GALDERMA GROUP AG
NYSE:GALDY
USA $13.39 Billion
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Galderma Group N
SW:GALD
Switzerland CHF12.88 Billion
Enzymatica publ AB
ST:ENZY
Sweden Skr149.24 Million
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
China CN¥13.98 Billion
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
China CN¥17.01 Billion
Kangmei Pharmaceutical Co Ltd
SHG:600518
China CN¥13.68 Billion
Walvax BioTech
SHE:300142
China CN¥10.50 Billion

H Lundbeck A/S - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.44 1.52 1.02
Quick Ratio 0.94 1.05 0.69
Cash Ratio 0.00 0.00 0.00
Working Capital Dkr3.93 Billion Dkr4.43 Billion Dkr143.00 Million

H Lundbeck A/S - Advanced Valuation Insights

This section examines the relationship between H Lundbeck A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.41
Latest Market Cap to Assets Ratio 0.03
Asset Growth Rate (YoY) -5.2%
Total Assets Dkr54.01 Billion
Market Capitalization $1.56 Billion USD

Valuation Analysis

Below Book Valuation: The market values H Lundbeck A/S's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: H Lundbeck A/S's assets decreased by 5.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for H Lundbeck A/S (2004–2025)

The table below shows the annual total assets of H Lundbeck A/S from 2004 to 2025.

Year Total Assets Change
2025-12-31 Dkr54.01 Billion
≈ $8.45 Billion
-5.20%
2024-12-31 Dkr56.98 Billion
≈ $8.91 Billion
+52.31%
2023-12-31 Dkr37.41 Billion
≈ $5.85 Billion
-0.12%
2022-12-31 Dkr37.45 Billion
≈ $5.86 Billion
+8.08%
2021-12-31 Dkr34.65 Billion
≈ $5.42 Billion
-3.82%
2020-12-31 Dkr36.03 Billion
≈ $5.64 Billion
+0.76%
2019-12-31 Dkr35.76 Billion
≈ $5.59 Billion
+55.39%
2018-12-31 Dkr23.01 Billion
≈ $3.60 Billion
+16.48%
2017-12-31 Dkr19.76 Billion
≈ $3.09 Billion
-2.25%
2016-12-31 Dkr20.21 Billion
≈ $3.16 Billion
-5.23%
2015-12-31 Dkr21.32 Billion
≈ $3.34 Billion
-16.82%
2014-12-31 Dkr25.64 Billion
≈ $4.01 Billion
+8.41%
2013-12-31 Dkr23.65 Billion
≈ $3.70 Billion
+9.67%
2012-12-31 Dkr21.56 Billion
≈ $3.37 Billion
+5.01%
2011-12-31 Dkr20.53 Billion
≈ $3.21 Billion
+14.05%
2010-12-31 Dkr18.00 Billion
≈ $2.82 Billion
+5.13%
2009-12-31 Dkr17.13 Billion
≈ $2.68 Billion
+35.86%
2008-12-31 Dkr12.61 Billion
≈ $1.97 Billion
+2.28%
2007-12-31 Dkr12.33 Billion
≈ $1.93 Billion
+5.98%
2006-12-31 Dkr11.63 Billion
≈ $1.82 Billion
+0.02%
2005-12-31 Dkr11.63 Billion
≈ $1.82 Billion
+1.04%
2004-12-31 Dkr11.51 Billion
≈ $1.80 Billion
--

About H Lundbeck A/S

CO:HLUN-A Denmark Drug Manufacturers - Specialty & Generic
Market Cap
$1.56 Billion
Dkr9.95 Billion DKK
Market Cap Rank
#6801 Global
#42 in Denmark
Share Price
Dkr50.00
Change (1 day)
+1.32%
52-Week Range
Dkr31.65 - Dkr50.00
All Time High
Dkr50.00
About

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat maj… Read more